RU2526804C2 - Конъюгированные белки с пролонгированным действием in vivo - Google Patents
Конъюгированные белки с пролонгированным действием in vivo Download PDFInfo
- Publication number
- RU2526804C2 RU2526804C2 RU2011106573/15A RU2011106573A RU2526804C2 RU 2526804 C2 RU2526804 C2 RU 2526804C2 RU 2011106573/15 A RU2011106573/15 A RU 2011106573/15A RU 2011106573 A RU2011106573 A RU 2011106573A RU 2526804 C2 RU2526804 C2 RU 2526804C2
- Authority
- RU
- Russia
- Prior art keywords
- protein
- exercise
- albumin
- nhc
- albumin binding
- Prior art date
Links
- 0 CCC(C)(C)CC(C)(C)CS(NC(*)(*)*)(=O)=O Chemical compound CCC(C)(C)CC(C)(C)CS(NC(*)(*)*)(=O)=O 0.000 description 7
- MWCIMXKQXCTLAZ-UHFFFAOYSA-N CCCNc(cc1)ccc1C(NCCCCC(C(N)=O)NC(CCC(C)(C)OCCC(C)(C)OCCNC(C(CCC(O)=O)NC(CCC(C(O)=O)NC(C1CCC(CNC)CC1)=O)=O)=O)=O)=O Chemical compound CCCNc(cc1)ccc1C(NCCCCC(C(N)=O)NC(CCC(C)(C)OCCC(C)(C)OCCNC(C(CCC(O)=O)NC(CCC(C(O)=O)NC(C1CCC(CNC)CC1)=O)=O)=O)=O)=O MWCIMXKQXCTLAZ-UHFFFAOYSA-N 0.000 description 1
- RUXHGLLCUSSHEH-XJLZTBPZSA-N CCCNc(cc1)ccc1C(NCCCCC(C(N)=O)NC(CCOCCOCCNC(C(CCC(O)=O)NC(CC[C@@H](C(O)=O)NC(C1CCC(CNC)CC1)=O)=O)=O)=O)=O Chemical compound CCCNc(cc1)ccc1C(NCCCCC(C(N)=O)NC(CCOCCOCCNC(C(CCC(O)=O)NC(CC[C@@H](C(O)=O)NC(C1CCC(CNC)CC1)=O)=O)=O)=O)=O RUXHGLLCUSSHEH-XJLZTBPZSA-N 0.000 description 1
- BKNCSFCANGKGIN-MOKVQWQQSA-N CCCNc(cc1)ccc1C(NCCCC[C@@H](C(O)=O)NC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CC(C1)C1(C(O)=O)NC(COCCOCCNC(CCC/S=[O]/CNC)=O)=O)=O)=O)=O)=O Chemical compound CCCNc(cc1)ccc1C(NCCCC[C@@H](C(O)=O)NC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CC(C1)C1(C(O)=O)NC(COCCOCCNC(CCC/S=[O]/CNC)=O)=O)=O)=O)=O)=O BKNCSFCANGKGIN-MOKVQWQQSA-N 0.000 description 1
- VVSJJAJHIKYCAL-UHFFFAOYSA-N CCCNc1ccc(CCC(NCCCCC(C(N)=O)NC(CCOCCOCCC(C(C(CCC(O)=O)C(C(CCC(C(C(C2CCCCC2)O)=N)C(O)=O)=O)=N)=O)=N)=O)=O)cc1 Chemical compound CCCNc1ccc(CCC(NCCCCC(C(N)=O)NC(CCOCCOCCC(C(C(CCC(O)=O)C(C(CCC(C(C(C2CCCCC2)O)=N)C(O)=O)=O)=N)=O)=N)=O)=O)cc1 VVSJJAJHIKYCAL-UHFFFAOYSA-N 0.000 description 1
- IINVIBZCXWVCAO-UHFFFAOYSA-N CCNCCS(C)(=O)=O Chemical compound CCNCCS(C)(=O)=O IINVIBZCXWVCAO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08161905 | 2008-08-06 | ||
| EP08161905.8 | 2008-08-06 | ||
| PCT/EP2009/060186 WO2010015668A1 (en) | 2008-08-06 | 2009-08-06 | Conjugated proteins with prolonged in vivo efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011106573A RU2011106573A (ru) | 2012-09-20 |
| RU2526804C2 true RU2526804C2 (ru) | 2014-08-27 |
Family
ID=41334423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011106573/15A RU2526804C2 (ru) | 2008-08-06 | 2009-08-06 | Конъюгированные белки с пролонгированным действием in vivo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8865868B2 (https=) |
| EP (1) | EP2323694A1 (https=) |
| JP (1) | JP5977945B2 (https=) |
| KR (1) | KR20110039348A (https=) |
| CN (1) | CN102112157B (https=) |
| AU (1) | AU2009279090A1 (https=) |
| BR (1) | BRPI0917000A2 (https=) |
| CA (1) | CA2733200A1 (https=) |
| MX (1) | MX2011000847A (https=) |
| RU (1) | RU2526804C2 (https=) |
| WO (1) | WO2010015668A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| WO2010071894A2 (en) | 2008-12-19 | 2010-06-24 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| JP6086528B2 (ja) * | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 長期のインビボ有効性を有する成長ホルモン |
| CN118767117A (zh) | 2010-01-22 | 2024-10-15 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| EP2536434B1 (en) * | 2010-02-16 | 2016-04-20 | Novo Nordisk A/S | Purification method |
| AU2011227714B2 (en) | 2010-03-19 | 2014-09-04 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| EP2595661A1 (en) * | 2010-07-22 | 2013-05-29 | Novo Nordisk Health Care AG | Growth hormone conjugates |
| BR112013021661A2 (pt) | 2011-03-02 | 2016-11-22 | Novo Nordisk As | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas |
| WO2012140647A2 (en) | 2011-04-11 | 2012-10-18 | Yeda Research And Development Co. Ltd | Albumin binding probes and drug conjugates thereof |
| EP4488289A3 (en) * | 2012-02-14 | 2025-03-19 | OPKO Biologics Ltd. | Long-acting coagulation factors and uses thereof |
| WO2013141965A1 (en) | 2012-03-21 | 2013-09-26 | Baxter International Inc. | Tfpi inhibitors and methods of use |
| BR112014025951A2 (pt) | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
| ES2629735T3 (es) * | 2012-05-08 | 2017-08-14 | Novo Nordisk A/S | Derivados de GLP-1 doblemente acilados |
| EA033788B1 (ru) | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
| US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
| FR3006315B1 (fr) * | 2013-05-31 | 2015-10-02 | Centre Nat Rech Scient | Microparticules et nanoparticules auto-associatives composees de proteines |
| FR3011470B1 (fr) | 2013-10-09 | 2017-01-06 | Centre Nat De La Rech Scient (Cnrs) | Composition antifongique comprenant un agent antifongique et du chitosane hydrophobise |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10583104B2 (en) | 2014-08-06 | 2020-03-10 | Indiana University Research And Technology Corporation | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis |
| HRP20230405T8 (hr) | 2014-12-10 | 2023-09-29 | Opko Biologics Ltd. | Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta |
| CR20170338A (es) * | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
| ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
| MY206271A (en) | 2016-07-11 | 2024-12-06 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
| US20240317832A1 (en) * | 2021-07-29 | 2024-09-26 | Novocodex Biopharmaceuticals Co., Ltd. | Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate |
| CN113698468B (zh) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8610551D0 (en) | 1986-04-30 | 1986-06-04 | Hoffmann La Roche | Polypeptide & protein derivatives |
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| ATE198353T1 (de) | 1988-08-24 | 2001-01-15 | American Cyanamid Co | Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| EP0397834B1 (en) | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| US5951972A (en) | 1990-05-04 | 1999-09-14 | American Cyanamid Company | Stabilization of somatotropins and other proteins by modification of cysteine residues |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| DK220890D0 (da) | 1990-09-14 | 1990-09-14 | Ole Buchardt | Fremgangsmaade til fremstilling af c-terminalt amiderede peptider |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| IT1251895B (it) | 1991-09-27 | 1995-05-26 | Eniricerche Spa | Mutanti dell'ormone della crescita umano e loro impiego |
| EP0555649B1 (en) | 1992-01-14 | 2004-12-08 | Ajinomoto Co., Inc. | Gene encoding transglutaminase derived from fish |
| ZA936811B (en) | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| JP3758187B2 (ja) | 1994-01-28 | 2006-03-22 | 味の素株式会社 | マガキ由来のトランスグルタミナーゼ |
| DE69535037T2 (de) | 1994-08-26 | 2006-12-07 | Novozymes A/S | Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| DE4437604A1 (de) | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| WO1996022366A1 (en) | 1995-01-19 | 1996-07-25 | Novo Nordisk A/S | Transglutaminases from oomycetes |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| CA2230492C (en) | 1995-09-21 | 2009-05-26 | Genentech, Inc. | Human growth hormone variants |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| EP0929576A1 (en) | 1996-08-30 | 1999-07-21 | Novo Nordisk A/S | Glp-2 derivatives |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6620916B1 (en) | 1996-09-26 | 2003-09-16 | Ajinomoto Co., Inc. | Modified physiologically active proteins and medicinal compositions containing the same |
| US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
| ATE375363T1 (de) | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| US6136536A (en) | 1997-10-29 | 2000-10-24 | Genetics Institute, Inc. | Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| AU2712899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates |
| EP1061946B1 (en) | 1998-02-27 | 2004-04-28 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| EP1062240B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| AU2610599A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| US6358705B1 (en) | 1998-07-16 | 2002-03-19 | Novo Nordisk A/S | Method of making proteins in transformed yeast cells |
| DE69922043T2 (de) | 1998-12-07 | 2005-11-24 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Glp-1 analoge |
| CA2363712C (en) | 1999-05-17 | 2011-05-10 | Conjuchem Inc. | Long lasting insulinotropic peptides |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| EP1198565A1 (en) | 1999-07-07 | 2002-04-24 | Maxygen Aps | A method for preparing modified polypeptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| GB2355009A (en) | 1999-07-30 | 2001-04-11 | Univ Glasgow | Peptides conjugated to bile acids/salts |
| US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| WO2001051071A2 (en) | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| DE60138364D1 (de) | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
| EP1352062A2 (en) | 2001-01-11 | 2003-10-15 | Maxygen Aps | Improved growth hormone molecules |
| US20060183197A1 (en) | 2001-01-11 | 2006-08-17 | Andersen Kim V | Variant growth hormone molecules conjugated with macromolecules compounds |
| FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| AU2002316811A1 (en) | 2001-06-28 | 2003-03-03 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| JP2004537580A (ja) | 2001-08-10 | 2004-12-16 | エピックス メディカル， インコーポレイテッド | 延長された循環半減期を有するポリペプチド結合体 |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| AP2004003050A0 (en) | 2001-11-20 | 2004-06-30 | Pharmacia Corp | Chemically modified human growth hormone conjugates |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| IL164266A0 (en) | 2002-04-10 | 2005-12-18 | Lilly Co Eli | Treatment of gastroparesis |
| SI1499719T1 (sl) | 2002-04-30 | 2011-03-31 | Bayer Healthcare Llc | Polipeptidne variante faktorja VII ali VIIa |
| DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| UA83816C2 (ru) | 2003-01-14 | 2008-08-26 | Тева Фармасьютикал Индастриз, Лтд | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ |
| JP2007524579A (ja) | 2003-02-19 | 2007-08-30 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１の類似体 |
| BRPI0409976A (pt) | 2003-05-09 | 2006-05-09 | Novo Nordisk As | composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto |
| EP1654004A2 (en) | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
| JP2007537981A (ja) | 2003-09-19 | 2007-12-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の血漿タンパク質親和性タグ |
| CN100580087C (zh) | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
| JP2007537142A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | アルブミン様物質に結合した新規のｇｌｐ−１類似物 |
| MXPA06006745A (es) | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Compuestos glp-1 novedosos. |
| EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ａｍｐｋ活性化剤 |
| US20070244202A1 (en) | 2004-06-28 | 2007-10-18 | Kao Corporation | Ampk Activator |
| MXPA06015049A (es) | 2004-07-08 | 2007-02-08 | Novo Nordisk As | Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol. |
| JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｆｖｉｉの抱合体 |
| US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
| JP5755398B2 (ja) | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2006122982A1 (en) | 2005-05-20 | 2006-11-23 | Novo Nordisk Health Care Ag | New poly(ethylene glycol) derivatives and process for their coupling to proteins |
| WO2006134174A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Dimeric and multimeric fviia compound |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| CN101263225A (zh) | 2005-08-18 | 2008-09-10 | 诺沃-诺迪斯克保健股份有限公司 | 改进转谷氨酰胺酶的底物特异性 |
| JP5486809B2 (ja) | 2006-02-14 | 2014-05-07 | ノボ ノルディスク ヘルス ケア アーゲー | Ｃ末端におけるポリペプチドの結合 |
| BRPI0713963A2 (pt) * | 2006-07-07 | 2012-11-27 | Novo Nordisk Healthcare Ag | conjugados de proteìna e métodos para sua preparação |
| EP2046736B1 (en) | 2006-07-27 | 2019-06-12 | Emisphere Technologies, Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
| JP2010500886A (ja) | 2006-08-18 | 2010-01-14 | ノボ ノルディスク ヘルス ケア アーゲー | 改善された特異性を有するトランスグルタミナーゼ変異体 |
| US20080095837A1 (en) | 2006-08-31 | 2008-04-24 | Emisphere Technologies, Inc. | Human growth hormone formulations |
| AU2007289344B2 (en) | 2006-08-31 | 2011-04-14 | Novartis Ag | Pharmaceutical compositions comprising hGH for oral delivery |
| JP5390404B2 (ja) | 2007-02-16 | 2014-01-15 | エミスフェアー・テクノロジーズ・インク | 活性薬剤を送達するための環状部分を有する化合物及び組成物 |
| US20100261637A1 (en) | 2007-09-05 | 2010-10-14 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| KR20110039348A (ko) | 2008-08-06 | 2011-04-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질 |
| US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| JP5816097B2 (ja) | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| EP2398822B1 (en) * | 2009-02-19 | 2013-01-02 | Novo Nordisk A/S | Modification of factor viii |
-
2009
- 2009-08-06 KR KR1020117003464A patent/KR20110039348A/ko not_active Withdrawn
- 2009-08-06 MX MX2011000847A patent/MX2011000847A/es active IP Right Grant
- 2009-08-06 AU AU2009279090A patent/AU2009279090A1/en not_active Withdrawn
- 2009-08-06 US US13/055,871 patent/US8865868B2/en not_active Expired - Fee Related
- 2009-08-06 JP JP2011521577A patent/JP5977945B2/ja not_active Expired - Fee Related
- 2009-08-06 RU RU2011106573/15A patent/RU2526804C2/ru not_active IP Right Cessation
- 2009-08-06 EP EP09781544A patent/EP2323694A1/en not_active Withdrawn
- 2009-08-06 CA CA2733200A patent/CA2733200A1/en not_active Withdrawn
- 2009-08-06 CN CN2009801309611A patent/CN102112157B/zh not_active Expired - Fee Related
- 2009-08-06 BR BRPI0917000A patent/BRPI0917000A2/pt not_active IP Right Cessation
- 2009-08-06 WO PCT/EP2009/060186 patent/WO2010015668A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005027978A2 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
Non-Patent Citations (1)
| Title |
|---|
| SZENTE L et al "Fatty Acid-Cyclodextrin Complexes: Properties and Applications" j. of Inclusion Phenomena and Molecular Recognition in Chemistry, 1993, 16, pp.339-340/ * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5977945B2 (ja) | 2016-08-24 |
| US8865868B2 (en) | 2014-10-21 |
| EP2323694A1 (en) | 2011-05-25 |
| WO2010015668A1 (en) | 2010-02-11 |
| CN102112157A (zh) | 2011-06-29 |
| US20110223151A1 (en) | 2011-09-15 |
| CA2733200A1 (en) | 2010-02-11 |
| KR20110039348A (ko) | 2011-04-15 |
| CN102112157B (zh) | 2013-05-29 |
| JP2011529948A (ja) | 2011-12-15 |
| BRPI0917000A2 (pt) | 2016-02-16 |
| RU2011106573A (ru) | 2012-09-20 |
| MX2011000847A (es) | 2011-02-25 |
| AU2009279090A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2526804C2 (ru) | Конъюгированные белки с пролонгированным действием in vivo | |
| JP5209463B2 (ja) | アシル化ｇｌｐ−１化合物 | |
| JP6086528B2 (ja) | 長期のインビボ有効性を有する成長ホルモン | |
| CN1909930B (zh) | 转谷氨酰胺酶介导的肽的接合 | |
| JP5755398B2 (ja) | 伸長されたｇｌｐ−１化合物 | |
| JP5606314B2 (ja) | Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途 | |
| AU2012255119A1 (en) | Improved peptide pharmaceuticals for insulin resistance | |
| JP2010538049A (ja) | 切断型ｇｌｐ−１誘導体及びその治療的使用 | |
| RS59459B1 (sr) | Hormoni rasta sa produženom in-vivo efikasnošću | |
| JP2008545644A (ja) | 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法 | |
| ES2745484T3 (es) | Hormonas de crecimiento con eficacia prolongada in vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150807 |